Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Rare Diseases 1Neurologic Manifestations 1Mental Disorders 1Lambert-Eaton Myasthenic Syndrome 1

Interventions

Exercise 439Blood Specimen Collection 333Standard of Care 321Magnetic Resonance Spectroscopy 258Radiotherapy 255Surveys and Questionnaires 245Radiosurgery 245Educational Status 230Methods 229Early Intervention, Educational 218Practice Guidelines as Topic 146Interviews as Topic 146Biopsy 145Surgical Procedures, Operative 134Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 110Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 95Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Radiotherapy, Intensity-Modulated 79Colonoscopy 79Specimen Handling 78Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Interventional × Amifampridine × Clear all
NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡